Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting

Journal of the Medical Association of Thailand

Volumn 97, Issue 3, 2014, Pages 349-355

  Chanthawong, Suthan ^a   Subongkot, Suphat ^a   Sookprasert, Aumkhae ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Breakthrough vomiting; Chemotherapy induced nausea and vomiting; Dexamethasone; Metoclopramide; Olanzapine; Ondansetron

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RETCHING; RISK FACTOR; SOLID TUMOR; TREATMENT RESPONSE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING;

EID: 84902287905     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008; 14: 85-93.
2. Hickok JT, Roscoe JA, Morrow GR, Giguere JK, Colman LK, Malcolm A. Effect of nausea vs. vomiting on patients' quality of life during chemotherapy. J Clin Oncol 2006; 24(18S): 8514.
3. Multinational Association of Supportive Care in Cancer (MASCC). MASCC/ESMO Antiemetic Guidelines [Internet]. 2011 [cited 2012 Jan 9]. Available from: http://data.memberclicks.com/ site/mascc/MASCC_Guidelines_English_2011.pdf
4. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-98.
5. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: antiemesis, V.1 [Internet]. 2014 [cited 2013 Nov 3]. Available from: http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf
6. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 2007; 16: 351-4.
7. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602-8.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
9. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526-32.
10. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25: 578-82.
11. Kitada T, Narimatsu T, Yamaguchi S. Olanzapine as an antiemetic in intractable nausea and anorexia in patients with advanced hepatocellular carcinoma: three case series. Kanzo 2009; 50: 153-8.
12. Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007; 15: 1285-91.
13. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapyinduced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188-95.
14. Rhodes VA, McDaniel RW. The index of nausea, vomiting, and retching: a new format of the index of nausea and vomiting. Oncol Nurs Forum 1999; 26: 889-94.
15. National Cancer Institute-Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [Internet]. 2009 [cited 2013 Jul 1]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
16. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32-43.
17. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9.
18. MICROMEDEX®2.0 [Internet]. Colorado: Thomson Reuters (Healthcare). DRUGDEX® system, olanzapine [Internet]. c1974-2012 [cited 2013 Oct 1]. Available from: http://www.thomsonhc.com
19. Navari RM, Gray SE. Treatment of chemotherapyinduced breakthrough nausea and vomiting. Annual Meeting of the American Society of Clinical Oncology (ASCO), Abstract e20536 [Internet]. 2009 [cited 2013 Oct 1]. Available from: http://meetinglibrary.asco.org/content/ 31334-65
20. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21: 1655-63.
21. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007; 9: 618-27.
22. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364-72.
23. Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28: 131.